Opinion|Videos|October 13, 2023
Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)
Author(s)Robert J. Motzer, MD, Elizabeth Plimack, MD
Robert Motzer, MD, presents the patient profile of a 65-year-old man diagnosed with clear cell RCC for discussion.
Advertisement
Episodes in this series
Advertisement
Related to this article
Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.
Gov. Hochul unveils a cell and gene therapy fellowship between Roswell Park and San Juan City Hospital to train Puerto Rico physicians in advanced cancer care.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
A meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
Advertisement
Advertisement
Trending on OncLive
1
First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian Cancer
2
LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Sonrotoclax-Based Regimens Elicit Responses in Relapsed/Refractory MCL
4
Dr Borgen on Matching Treatment to HER2 Biology in Early-Stage HER2-Positive Breast Cancer
5